Viyash Scientific Latest News: Viyash Scientific Ltd Scales 52-Week High of Rs 277.35 on 23 June 2026 Backed by Strong Fundamentals
- June 23, 2026
- Posted by: Neeraj Pandey
- Category: News
Viyash Scientific latest news: NSE: VIYASH Rs 275.1 (23 June 2026). 52W high Rs 277.35. 52W low Rs 166. MCap Rs 11,138 Cr. P/E ~146x. 1Y return +~35%.
Viyash Scientific Latest News is drawing investor attention as Viyash Scientific Ltd (NSE: VIYASH) reached a 52-week high of Rs 277.35 in the current trading session on 23 June 2026, extending a powerful rally that has returned ~35% to investors over the past year from its 52-week low of Rs 166. The Animal Health Pharmaceuticals company is backed by strong fundamental performance and significant business developments that continue to fuel the Viyash Scientific latest news momentum.
This Viyash Scientific latest news analysis covers the key catalysts behind the 52-week high, what market analysts are observing about the stock’s near-term trajectory, the next price targets and levels to watch, and the key risks investors should monitor.
Click Here – Get Free Investment Predictions
About Viyash Scientific Ltd: Company Overview
Formerly Sequent Scientific, renamed Viyash Scientific in January 2026, the company is a globally integrated animal health pharmaceutical company focused on APIs, finished dosage formulations, and analytical services for veterinary healthcare. It operates eight manufacturing facilities across India, Turkey, Brazil, Spain, and Germany, serving livestock, poultry, and companion animal segments.
| Metric | Value |
|---|---|
| CMP (23 June 2026) | Rs 275.1 |
| 52-Week High | Rs 277.35 |
| 52-Week Low | Rs 166 |
| Market Cap | Rs 11,138 Cr |
| P/E Ratio (TTM) | ~146x |
| Sector | Animal Health Pharmaceuticals |
| 1-Year Return | +~35% |
| NSE Symbol | NSE: VIYASH |
Viyash Scientific Latest News: What Is Driving the 52-Week High?
The Viyash Scientific latest news of a 52-week high breakout is driven by three key developments that have fundamentally strengthened the company’s earnings and growth outlook.
Q4 FY26 Net Profit Surged 459% Year-on-Year
Viyash Scientific posted Q4 FY26 consolidated net profit of Rs 52.11 crore, a 459.12% surge year-on-year and 35.56% quarter-on-quarter, following a dramatic operational turnaround. Q4 revenue rose 129% year-on-year, reflecting the ramp-up of new formulation products and the normalisation of input costs across its European manufacturing operations.
ICRA Upgrade to AA/Stable Rating
ICRA upgraded Viyash Scientific’s long-term rating to ICRA AA/Stable and its short-term rating to ICRA A1+ as of April 22, 2026, a significant credit quality upgrade. India Ratings also upgraded the company’s long-term rating to IND AA/Stable. These upgrades reflect substantial improvement in the company’s financial health, debt reduction, and business stability following several years of restructuring.
15% Annual Revenue Growth Target for FY27
Viyash Scientific’s management targets 15% annual revenue growth for FY26 to FY28, driven by new product launches across anthelmintics, anti-protozoals, and nutraceuticals, capacity expansion at its European facilities, and gaining market share in regulatory markets. The company emphasises a strong balance sheet with net debt to EBITDA improving to 0.2x in Q4 FY26.
Use the Univest Screener to Track Live Price and Key Fundamentals
What Market Analysts Are Saying About Viyash Scientific Latest News
Market analysts are broadly positive on Viyash Scientific following its credit rating upgrade and dramatic Q4 FY26 earnings recovery. The company is classified as ‘Technically Bullish’ on market analysis platforms, with a Hold-to-Accumulate rating reflecting the strong turnaround momentum. Full-year FY26 PAT of Rs 224.65 crore on revenue of Rs 3,463.86 crore marks a full recovery from the losses of earlier years.
Ankit Jaiswal, Senior Research Analyst at Univest, notes that the Viyash Scientific latest news breakout is supported by genuine fundamental strength, with the company’s recent earnings trajectory and business developments providing a credible basis for the re-rating. He observes that the sector outlook remains supportive and that the stock’s technical structure, trading above all major moving averages, adds conviction to the bullish view, though he also flags that valuation has moved ahead of near-term earnings estimates at the current price.
Kunal Singla, Research Analyst at Univest, observes that the Viyash Scientific latest news of a 52-week high is technically significant, as the stock is now in uncharted territory with no historical supply overhang above current levels. He notes that as long as the stock holds the Rs 240 level on weekly closes, the trend structure remains intact and the path of least resistance is upward. Singla recommends watching Q1 FY27 results as the key fundamental confirmation signal for the next leg of the Viyash Scientific latest news rally.
Viyash Scientific Latest News: Next Share Price Targets and Key Levels
Based on technical analysis and available analyst data, the following are the key price levels associated with the Viyash Scientific latest news story that investors and traders are monitoring.
| Level | Price (Rs) | Significance |
|---|---|---|
| 52-Week High (Current) | 277.35 | New breakout level as of 23 June 2026 |
| Near-Term Target | 300 to 330 | Based on technical momentum and analyst views |
| Key Support | 240 | Weekly close support; breakdown = trend risk |
These levels are derived from publicly available technical analysis and analyst commentary and should not be treated as guaranteed targets or investment advice. Investors should use these as reference points while monitoring the broader Animal Health Pharmaceuticals sector conditions and company-specific earnings developments.
Key Risks to Monitor
Valuation at Premium Levels
At a P/E of ~146x, the Viyash Scientific latest news rally has priced in a significant amount of future growth. Any earnings disappointment in the coming quarters could trigger a sharp correction from these elevated levels. Investors should carefully assess the risk-reward before initiating new positions at or near the current 52-week high.
Sector and Macro Headwinds for Animal Health Pharmaceuticals
The Animal Health Pharmaceuticals sector is subject to broader macro risks including changes in government capex priorities, commodity price movements affecting input costs, and global economic conditions influencing demand. A slowdown in any of these factors could weigh on the stock even if the company’s fundamental execution remains strong.
FII Selling and Liquidity Risk
With the stock at a 52-week high, foreign institutional investors may choose to book profits in line with their portfolio rebalancing strategies. A sustained period of FII selling in the Animal Health Pharmaceuticals space could create near-term price pressure regardless of the company’s fundamental outlook. Monitor FII/DII activity alongside the Viyash Scientific latest news price action.
Conclusion
The Viyash Scientific latest news of a 52-week high on 23 June 2026 is backed by strong fundamental performance, clear business catalysts, and a bullish technical structure across all major moving average timeframes. Ankit Jaiswal of Univest notes the fundamental story is compelling and the near-term trajectory remains positive as long as the stock holds above key support levels. Kunal Singla observes the technical breakout signals continued momentum but recommends monitoring Q1 FY27 earnings as the critical confirmation signal. Investors should track the Nifty Pharma for sector-level signals alongside company-specific developments. Please consult a SEBI-registered investment advisor before making any investment decision.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Download the Univest iOS App or Univest Android App to track Viyash Scientific Ltd live price and receive expert daily stock research.
Frequently Asked Questions on Viyash Scientific Latest News
What is the Viyash Scientific latest news today?
Ans. The Viyash Scientific latest news today is that Viyash Scientific Ltd (NSE: VIYASH) reached a 52-week high of Rs 277.35 on 23 June 2026. The stock has returned ~35% over the past year from its 52-week low of Rs 166, driven by q4 fy26 net profit surged 459% year-on-year and other key catalysts.
Why did Viyash Scientific Ltd stock hit a 52-week high?
Ans. Viyash Scientific Ltd stock hit a 52-week high due to q4 fy26 net profit surged 459% year-on-year, icra upgrade to aa/stable rating, and 15% annual revenue growth target for fy27. These developments have materially improved the company’s earnings outlook and attracted sustained buying interest from domestic institutional and retail investors.
What is the Viyash Scientific latest news share price target?
Ans. Based on market analyst views and technical analysis, the near-term price target range for Viyash Scientific Ltd is Rs 300 to 330. Key support is at Rs 240 on weekly closes. These are technical observations and should not be treated as guaranteed investment targets. Consult a SEBI-registered advisor before investing.
What do analysts say about Viyash Scientific Ltd latest news?
Ans. Market analysts are broadly positive on Viyash Scientific following its credit rating upgrade and dramatic Q4 FY26 earnings recovery. The company is classified as ‘Technically Bullish’ on market analy Ankit Jaiswal and Kunal Singla of Univest both observe that the fundamental story is supported by strong earnings and the technical structure remains bullish as long as the stock holds above key support levels.
What is Viyash Scientific Ltd’s market cap and valuation?
Ans. As of 23 June 2026, Viyash Scientific Ltd’s market capitalisation is approximately Rs 11,138 crore, with a P/E ratio of ~146x. The stock is trading in the Animal Health Pharmaceuticals sector and has returned ~35% over the past year. Verify all data with official NSE and BSE sources before making any investment decision.
What are the key risks in Viyash Scientific Ltd latest news?
Ans. Key risks in the Viyash Scientific latest news story include stretched valuation at ~146x P/E, which already prices in significant growth expectations. Any earnings miss in Q1 FY27, sector-level macro headwinds for the Animal Health Pharmaceuticals segment, or sustained FII profit-booking could trigger a correction from the current 52-week high levels.
How can I track and invest in Viyash Scientific Ltd stock?
Ans. You can track the Viyash Scientific latest news and live price for Viyash Scientific Ltd on NSE under the symbol NSE: VIYASH. For live price data, fundamental analysis, and expert research, use the Univest screener and app. Investments in equity securities carry market risk. Please consult a SEBI-registered investment advisor before making any investment decision.
